CA-CYARA
19.7.2022 17:02:14 CEST | Business Wire | Press release
Cyara , provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today unveiled innovative new chatbot testing features with the latest release of Cyara Botium , the industry’s leading one-stop solution for comprehensive, automated chatbot testing and assurance. The release comes just weeks after Cyara announced its acquisition of Botium to solidify its position as the global leader in CX testing and assurance.
Chatbots continue to experience tremendous growth driven by the meaningful benefits they deliver to businesses and customers alike, but they’re also commonly plagued with problems that include misinterpreted customer intent, delayed or disrupted hand-offs to live agents and security vulnerabilities. Negative chatbot experiences can have a devastating impact on a brand and result in customer churn.
The disconnect between what chatbots generally promise and what they deliver has created the need for solutions that can efficiently test and monitor the performance of chatbots and conversational AI without overburdening teams. With Cyara Botium’s holistic testing approach, brands can improve and continuously test the customer chatbot experience across all channels and platforms in all phases of the chatbot development lifecycle. Cyara Botium also addresses the rise in chatbot data breaches by improving general chatbot security, ensuring compliance with Open Web Application Security Project® (OWASP) security standards. The result: consistent, quality, secure experiences and, for new bots, shortened time to market.
Cyara Botium offers the following new features and capabilities:
AI-Powered Data & Test Generation
Cyara Botium’s new AI-Powered Data & Test Generation is built on the world’s largest natural language model. This enables organizations to quickly create relevant examples of intents and utterances in order to thoroughly train and test their chatbots. This cutting-edge feature dramatically improves the efficiency of chatbot teams, requiring mere minutes to generate new intent phrasing to the chatbot—an otherwise laborious, manual process that can take weeks to collect data from various sources. By using the largest pre-trained language model through Cyara Botium, customers can save AI-generated topics as new intents – thereby dramatically improving the chatbot’s ability to understand what the user is trying to achieve.
Extended Performance Testing
Cyara Botium has greatly enhanced the scalability of its performance testing by dramatically increasing the capacity of parallel test executions so that chatbot development teams can stress test by simulating very high volumes of interactions.
Interactive Voice Response (IVR) Channel and Voice Testing
The new release of Cyara Botium introduces two new test types. Users can now test bots in the IVR channel, ensuring they perform effectively as part of an IVR experience by generating calls that mimic real-time customer interactions. Users can also now conduct voice tests to ensure voicebots perform well in all environments, including mobile devices and browsers. Both of these new features ensure problems are unearthed well before they occur in production.
“It’s without question that chatbots are delivering benefits to businesses, but it’s imperative that organizations also realize that negative chatbot experiences can lead to chatbots hurting the business more than they help,” said Christoph Börner, Senior Director of Digital at Cyara. “Cyara Botium has already been a prominent market leader in testing conversational AI and is well ahead of the market needs. The innovative features introduced in this release reinforce our leadership, setting us even further ahead of any competition.”
Additional new features include multi-language General Data Protection Regulation (GDPR) testing for compliance with European Union (EU) security protocols, customizable reporting templates that appeal to any stakeholder and Single Sign-On (SSO) user authentication.
To learn more about Cyara Botium, please click here .
About Cyara’s Automated CX Assurance Platform
The award-winning Cyara Automated CX Assurance Platform enables companies to deliver better CX with less effort, cost, and risk. Cyara supports the entire CX software development lifecycle, from design to functional and regression testing, load testing, chatbot testing and production monitoring, ensuring enterprises can build flawless customer journeys across voice and digital channels.
About Cyara
Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005044/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom